Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.55 Insider Own12.43% Shs Outstand28.49M Perf Week-7.56%
Market Cap47.01M Forward P/E- EPS next Y-0.12 Insider Trans0.00% Shs Float24.95M Perf Month-15.38%
Income-9.29M PEG- EPS next Q-0.07 Inst Own18.23% Short Float / Ratio3.55% / 3.31 Perf Quarter-23.26%
Sales80.83M P/S0.58 EPS this Y78.84% Inst Trans10.99% Short Interest0.88M Perf Half Y-63.82%
Book/sh0.76 P/B2.18 EPS next Y68.75% ROA-17.39% Target Price8.00 Perf Year54.21%
Cash/sh0.41 P/C4.01 EPS next 5Y38.00% ROE-49.33% 52W Range0.94 - 6.24 Perf YTD62.56%
Dividend- P/FCF- EPS past 5Y19.45% ROI-32.94% 52W High-73.56% Beta1.33
Dividend %- Quick Ratio1.06 Sales past 5Y5.19% Gross Margin10.11% 52W Low75.16% ATR0.13
Employees253 Current Ratio1.32 Sales Q/Q27.18% Oper. Margin-10.01% RSI (14)37.06 Volatility6.67% 7.40%
OptionableYes Debt/Eq0.69 EPS Q/Q82.91% Profit Margin-11.49% Rel Volume1.52 Prev Close1.67
ShortableYes LT Debt/Eq0.31 EarningsNov 14 BMO Payout- Avg Volume267.04K Price1.65
Recom1.00 SMA20-13.04% SMA50-13.71% SMA200-36.00% Volume405,419 Change-1.20%
Date Action Analyst Rating Change Price Target Change
Jun-24-19Initiated Piper Jaffray Overweight $10
May-13-19Initiated H.C. Wainwright Buy $11
Nov-08-16Downgrade BofA/Merrill Neutral → Underperform
Mar-01-16Downgrade Stifel Buy → Hold
Aug-13-15Initiated Morgan Stanley Underweight $7
Jan-27-15Reiterated Oppenheimer Outperform $24 → $26
Jan-07-15Initiated Oppenheimer Outperform $24
Aug-14-14Initiated FBR Capital Underperform $6
Dec-19-13Initiated Chardan Capital Markets Buy $22
Nov-06-13Reiterated Summer Street Research Buy
Nov-15-23 01:29PM
Nov-14-23 10:36PM
06:00PM Loading…
Nov-07-23 06:00PM
Oct-26-23 06:00PM
Oct-20-23 06:15PM
Oct-18-23 06:00AM
Oct-17-23 06:00AM
Oct-16-23 06:00AM
Oct-13-23 06:15PM
Oct-03-23 06:15PM
Sep-28-23 06:00AM
06:15PM Loading…
Sep-27-23 06:15PM
Sep-21-23 06:15PM
Sep-18-23 11:37AM
Sep-07-23 06:00AM
Aug-15-23 12:29PM
Aug-14-23 10:53PM
Aug-11-23 10:28AM
Aug-10-23 10:00AM
Aug-09-23 06:00AM
Aug-01-23 06:25PM
Jul-26-23 06:00PM
Jul-21-23 06:15PM
06:00AM Loading…
Jul-17-23 06:00AM
Jul-12-23 10:00AM
Jul-11-23 06:00AM
Jul-03-23 09:35AM
Jun-29-23 06:00AM
Jun-28-23 09:26AM
Jun-27-23 12:00PM
Jun-26-23 06:00AM
Jun-23-23 07:43AM
Jun-20-23 06:09AM
Jun-19-23 08:50AM
Jun-08-23 10:18AM
Jun-01-23 08:50AM
May-15-23 08:55PM
May-11-23 08:50AM
May-01-23 06:00AM
Apr-27-23 06:00AM
Apr-25-23 08:50AM
Apr-17-23 07:34AM
Apr-12-23 08:12AM
Apr-11-23 09:41AM
Apr-06-23 08:50AM
Apr-01-23 12:11PM
Mar-30-23 06:00AM
Mar-27-23 06:00AM
Feb-28-23 06:00AM
Feb-16-23 06:00AM
Feb-13-23 07:48AM
Feb-02-23 07:00AM
Dec-13-22 06:00AM
Nov-17-22 05:31AM
Nov-14-22 06:00AM
Nov-09-22 06:00AM
Oct-17-22 06:00AM
Oct-13-22 06:21AM
Sep-14-22 04:15PM
Sep-07-22 08:00AM
Sep-02-22 07:03AM
Aug-30-22 01:27PM
Aug-18-22 08:50AM
Aug-15-22 06:00AM
Aug-03-22 06:00AM
Jun-24-22 08:56AM
Jun-23-22 07:07AM
Jun-22-22 04:02PM
Jun-07-22 08:00AM
Jun-01-22 08:00AM
May-31-22 08:00AM
May-23-22 08:00AM
May-16-22 04:02PM
May-12-22 10:53AM
May-11-22 08:00AM
Apr-29-22 08:25AM
Apr-25-22 08:00AM
Apr-20-22 08:00AM
Apr-11-22 09:00AM
Mar-15-22 09:00AM
Mar-09-22 09:00AM
Mar-01-22 08:55AM
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.